Manufacturer record
Trizal Formulation: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Trizal Formulation (Himachal Pradesh) were declared Not of Standard Quality between January 2023 and January 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
2 records linked to Trizal Formulation in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Voglibose Tablets IP (0.2 mg) | TV-880012Mfg 2022-02 · Exp 2024-01 | DisintegrationDisintegration | RDTL ChandigarhCDSCO lab | Jan 2023 |
| Loose yellow colored Tablets (Purported to contain Rosuvastatin 10 mg) | Not applicableMfg ? · Exp ? | Assay of RosuvastatinAssay | RDTL ChandigarhState lab | Jan 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.